Phase II Study of Pazopanib Monotherapy in Metastatic Gastroenteropancreatic Neuroendocrine Tumors Abstract #643

Introduction: Treatment options for patients with metastatic gastroenteropancreatic neuroendocrine tumors (GEP NETs) are still limited. The anti-angiogenic approach in metastatic pancreatic NETs has shown promising results.
Aim(s): We therefore investigated the anti-tumor activity and safety profile of pazopanib, a multi-target drug with antiangiogenic activity in patients with metastatic GEP NETs.
Materials and methods: This was a non-randomized, open-labeled, single center phase II study. Pazopanib was orally administered at a dose of 800 mg daily continuously with a 28-day cycle. The primary end point was an objective response rate according to RECIST version 1.1. The secondary endpoints were progression-free survival, overall survival and safety. An independent review of objective response was planned. Correlative biomarker analyses were performed.
Conference: 10th Annual ENETS Conference (2013)
Category: Medical treatment - Others
Presenting Author: Professor Young Suk Park
Keywords: Pazopanib, GEP-NETs

To read results and conclusion, please login ...

Further abstracts you may be interested in

#1059 Genomic Profiling of Metastatic Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET) Patients in Precision-Medicine Era
Introduction: We have conducted molecular profiling through high-throughput molecular test as part of clinical practice for patients with advanced gastrointestinal (GI) cancer, or rare cancer including gastroenteropancreatic neuroendocrine tumors (GEP-NETs).
Conference: 12th Annual ENETS Conference (2015)
Category: Basic Science - Genetics, epigenetics, miRNAs
Presenting Author: Seung Kim
Authors: Kim S, Yoo K, Jung K, Lee S, ...
#832 The Role of Plasma Chromogranin A as Assessment of Treatment Response in Grade 1-3 Non-Functioning Gastroenteropancreatic (GEP) Neuroendocrine Tumors
Introduction: Chromogranin A (CgA) is considered to be of value not only in diagnosis but also in monitoring the disease response to treatment. However, only a few studies have been published on this issue.
Conference: 11th Annual ENETS Conference (2014)
Category: Medical treatment - Chemotherapy
Presenting Author: Professor Young Park
Authors: Park Y, Kim S, Lee J, Park S, ...
#1268 The Impact of PD-L1 Expression in Patients with Metastatic GEP-NETs
Introduction: Programmed death-ligand 1 (PD-L1), which is expressed on many cancer cells, interacts with PD1 expressed on the surface of T cells, inhibiting the T cells and blocking the antitumor immune response.
Conference: 13th Annual ENETS conference (2016)
Category: Epidemiology/Natural history/Prognosis - Prognosis
Presenting Author: Seung Kim
Authors: Kim S, Park Y, ...
Keywords: PD-L1, GEP-NETs
#1580 The Impact of the Pathologic Differentiation (Well or Poorly) and the Degree of Ki-67 Index in Patients with Metastatic WHO Grade 3 GEP-NETs
Introduction: There is few data for the treatment-outcome with etoposide plus platinum between well differentiated and poorly differentiated metastatic grade 3 GEP-NEC.
Conference: 14th Annual ENETS conference (2017)
Category: Medical treatment - Others
Presenting Author: Seung Kim
Authors: Kim S, Park Y, ...
Keywords: Ki67 index
#432 Ten Years of Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs): Evolution of Classification and Correlation with Follow-up in 50 Patients
Introduction: In the last decade, GEP-NET nomenclature has been twice reviewed. The 2000 WHO classification had poor prognostic power in well-differentiated (WD) neoplasms which led to the introduction of two new important parameters: grade and stage, by ENETS; the former became part of the new 2010 WHO classification.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Prof Diego Ferone
Close
Notice

WARNING – FRAUDULENT WEBSITES

ENETS is aware that its members have been confronted with fake websites, which seem to relate to our congress but have not been commissioned or authorised by us. The websites offer fraudulent hotel reservation services. We therefore strongly recommend that you please only use the official enetsconference.org website when booking your tickets and accommodation. Please be vigilant when it comes to providing your credit card details. 

If you have any questions, please do not hesitate to contact us at info@enets.org.